Inspire Medical Systems (INSP) Stock Looks Near Fair Value As Shares Fell 82%
Inspire Medical Systems stock is coming under fresh scrutiny after a steep share price decline over the past few years, while the current valuation checks send a more neutral signal, with the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples no longer flagging an obvious bargain at the latest close near US$50.81.
- Over the past 3 years, Inspire Medical Systems shareholders have seen the share price fall about 82%, which puts the current valuation discussion front and center for anyone still holding or considering the stock.
- Future growth in revenue and cash flows from Inspire Medical Systems' sleep apnea therapy franchise can support today’s price, but execution risks around scaling the business and controlling costs may weigh on what investors are willing to pay.
- On Simply Wall St’s checks, Inspire Medical Systems scores 4 out of 6 on valuation, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether that combination of a severe past drawdown and a roughly fair intrinsic value leaves Inspire Medical Systems priced for a recovery in fundamentals or still vulnerable if expectations slip further.
Find out why Inspire Medical Systems' -60.5% return over the last year is lagging behind its peers.
Where Does Inspire Medical Systems Sit on Cash Flow?
The Discounted Cash Flow (DCF) model looks at the cash Inspire Medical Systems can generate for shareholders over time and discounts it back to today. On the latest figures, the company produced about $95.9 million of free cash flow over the last twelve months, and the model assumes cash flows that grow initially then flatten out rather than rising aggressively year after year.
On those assumptions, the DCF model points to an intrinsic value of about $55.91 per share, compared with the recent share price around $50.81. That implies the stock trades at roughly a 9.1% discount to the model’s estimate, which is close enough that small changes in cash flow, discount rates, or growth expectations could swing the result either side of “cheap” or “expensive”.
Overall, the DCF work suggests Inspire Medical Systems looks roughly fairly valued, with only a modest gap between estimated intrinsic value and the current share price.
Inspire Medical Systems is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Does Inspire Medical Systems Look Undervalued on Earnings?
The P/E ratio is a useful cross check for Inspire Medical Systems because it ties the share price directly to the earnings that support it. On this metric, Inspire Medical Systems currently trades at about 11.2x earnings, compared with an industry average P/E of roughly 26.4x for Medical Equipment companies and a peer group average near 53.3x.
Simply Wall St’s fair P/E estimate for Inspire Medical Systems is about 16.2x. This reflects what investors might typically pay given its profile, rather than just a raw sector average. Against that benchmark, the current 11.2x multiple sits well below the implied fair level. This suggests the stock is pricing in a more cautious outlook than the fair ratio would indicate.
Taken together, the P/E work indicates that Inspire Medical Systems stock may be undervalued on an earnings multiple basis.
See what the numbers say about this price — find out in our valuation breakdown.
The Inspire Medical Systems Narrative: What Would Justify Today's Price?
Simply Wall St Narratives aim to connect the current valuation puzzle around Inspire Medical Systems' stock with the different future paths the company could take, by making clear which expectations for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today’s price on the Community page. Each narrative links its number to a specific view on how Inspire Medical Systems' growth, profitability and risk profile might evolve, giving you something concrete to revisit as fresh information comes through.
The community is sharply split on Inspire Medical Systems, with one camp focusing on coding clarity as a reset opportunity and the other seeing it as a drag that could linger.
Bull case: 21% undervalued
"The post-transition acceleration in center additions and digital patient engagement investment is likely to produce compounding gains in share of newly diagnosed OSA patients…"
Read the full Bull Case to see why Inspire Medical Systems could be undervalued
Bear case: 30% overvalued
"Even as new reimbursement codes and proposed increases for Medicare are a near-term tailwind, the shift toward value-based care and outcomes-driven reimbursement models could force further downward adjustments to average selling prices…"
Read the full Bear Case to see why Inspire Medical Systems could be overvalued
Do you think there's more to the story for Inspire Medical Systems? Head over to our Community to see what others are saying!
The Bottom Line
Inspire Medical Systems now screens as roughly in line with its Discounted Cash Flow (DCF) intrinsic value estimate, while the earnings multiple points to the stock trading on an undervalued P/E. That mix fits a mixed valuation picture rather than a clear-cut opportunity or clear excess. For you, the key question is whether Inspire Medical Systems can deliver the revenue growth and cost control needed to support both cash flow and earnings without further execution missteps. The crux of the bull versus bear debate is whether today’s discount on earnings reflects caution that will ease over time or a market view that business risks remain underappreciated.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com